Send to

Choose Destination
J Rheumatol Suppl. 1994 Sep;41:86-9.

World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials.

Author information

Department of Internal Medicine/Rheumatology, University Hospital Maastricht, The Netherlands.


The WHO/ILAR core set of endpoints for rheumatoid arthritis clinical trials signifies progress in a continuing worldwide effort. This core set includes the following measures: pain, patient global assessment, physical disability, swollen joints, tender joints, acute phase reactants, and physician global assessment; in studies of one or more years' duration, radiographs of joints should be performed.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center